Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study)

被引：3

作者：

Rummel, Mathias ^{[1
]}

Buske, Christian ^{[2
]}

Hertenstein, Bernd ^{[3
]}

Lerchenmueller, Christian ^{[4
]}

Koenigsmann, Michael ^{[5
]}

Lange, Elisabeth ^{[6
]}

Reeb, Manfred ^{[7
]}

Kaiser, Ulrich ^{[8
]}

Balser, Christina

Behringer, Dirk ^{[9
]}

Duerig, Jan ^{[10
]}

Gaska, Tobias ^{[11
]}

Maschmeyer, Georg ^{[12
]}

Schliesser, Georg

Burchardt, Alexander C. ^{[1
]}

Barth, Juergen ^{[1
]}

Kauff, Frank ^{[1
]}

Hinke, Axel ^{[13
]}

Greil, Richard ^{[14
]}

机构：

[1] Univ Hosp Giessen, Med Clin 4, Hematol, Giessen, Germany

[2] Univ Hosp Ulm, Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany

[3] Klinikum Bremen Mitte, Med Klin 1, Bremen, Germany

[4] Outpatient Clin, Hematol & Oncol, Munster, Germany

[5] Outpatient Oncol Ctr, Hannover, Germany

[6] Evangel Krankenhaus Hamm, Hamm, Germany

[7] IDGGQ GbR, Kaiserslautern, Germany

[8] St Bernward Hosp, Hildesheim, Germany

[9] Augusta Kranken Anstalt gGmbH Bochum, Dept Haematol Oncol & Palliat Care, Bochum, Germany

[10] Univ Hosp Essen, Dept Haematol, Essen, Germany

[11] Bruderkrankenhaus St Josef, Hematol & Oncol, Paderborn, Germany

[12] Klinikum Ernst von Bergmann, Potsdam, Germany

[13] CCRC, Dusseldorf, Germany

[14] Univ Hosp Salzburg, Salzburg, Austria

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷

关键词：

Indolent lymphoma; non-hodgkin-lymphoma; Bendamustine; Rituximab maintenance;

D O I：

10.1016/j.clml.2018.06.072

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

FR-S26-NHL

引用

页码：S101 / S103

页数：3

共 6 条

[1] Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study
Mondello, Patrizia
Steiner, Normann
Willenbacher, Wolfgang
Cerchione, Claudio
Nappi, Davide
Mauro, Endri
Ferrero, Simone
Cuzzocrea, Salvatore
Mian, Michael
ONCOLOGIST, 2018, 23 (04): : 454 - 460
[2] Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi
Margiotta-Casaluci, Gloria
Bigliardi, Sara
Cocito, Federica
Meli, Erika
Petrucci, Luigi
Nicolosi, Maura
Annibali, Ombretta
Boccomini, Carola
Bozzoli, Valentina
Castellino, Alessia
Cattina, Federica
Cenfra, Natalia
Ciavarella, Sabino
Kovalchuk, Sofya
Rotondo, Francesco
Fama, Angelo
Olivieri, Jacopo
Zaja, Francesco
FRONTIERS IN ONCOLOGY, 2023, 13
[3] Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study
Mondello, Patrizia
Steiner, Normann
Willenbacher, Wolfgang
Wasle, Ines
Zaja, Francesco
Zambello, Renato
Visentin, Andrea
Mauro, Endri
Ferrero, Simone
Ghione, Paola
Pitini, Vincenzo
Cuzzocrea, Salvatore
Mian, Michael
ANNALS OF HEMATOLOGY, 2016, 95 (07) : 1107 - 1114
[4] Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study
Patrizia Mondello
Normann Steiner
Wolfgang Willenbacher
Ines Wasle
Francesco Zaja
Renato Zambello
Andrea Visentin
Endri Mauro
Simone Ferrero
Paola Ghione
Vincenzo Pitini
Salvatore Cuzzocrea
Michael Mian
Annals of Hematology, 2016, 95 : 1107 - 1114
[5] First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4
Walewski, Jan
Paszkiewicz-Kozik, Ewa
Michalski, Wojciech
Rymkiewicz, Grzegorz
Szpila, Tomasz
Butrym, Aleksandra
Giza, Agnieszka
Zaucha, Jan M.
Kalinka-Warzocha, Ewa
Wieczorkiewicz, Agata
Zimowska-Curylo, Dagmara
Knopinska-Posluszny, Wanda
Tyczynska, Agata
Romejko-Jarosinska, Joanna
Dabrowska-Iwanicka, Anna
Gruszecka, Beata
Jamrozek-Jedlinska, Maria
Borawska, Anna
Holda, Waldemar
Porowska, Agnieszka
Romanowicz, Agnieszka
Hellmann, Andrzej
Stella-Holowiecka, Beata
Deptala, Andrzej
Jurczak, Wojciech
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (06) : 898 - 906
[6] A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Lopez-Guillermo, Armando
Canales, Miguel Angel
Dlouhy, Ivan
Mercadal, Santiago
Briones, Javier
Martin Garcia-Sancho, Alejandro
Sancho, Juan Manuel
Maria Moraleda, Jose
Terol, Maria Jose
Salar, Antonio
Palomera, Luis
Gardella, Santiago
Jarque, Isidro
Ferrer, Secundino
Bargay, Joan
Lopez, Andres
Panizo, Carlos
Muntanola, Anna
Montalban, Carlos
Conde, Eulogio
Hernandez, Miguel T.
Soler, Alfons
Garcia Marco, Jose A.
Deben, Guillermo
Marin, Julian
Tomas, Jose Francisco
LEUKEMIA & LYMPHOMA, 2022, 63 (01) : 93 - 100

← 1 →